KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Shares Outstanding (Weighted Average) (2017 - 2025)

Pfizer (PFE) has disclosed Shares Outstanding (Weighted Average) for 17 consecutive years, with $5.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.34% to $5.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $5.7 billion, a 0.34% change, with the full-year FY2025 number at $5.7 billion, changed 0.34% from a year prior.
  • Shares Outstanding (Weighted Average) was $5.7 billion for Q4 2025 at Pfizer, roughly flat from $5.7 billion in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $5.7 billion in Q2 2025 to a low of $5.6 billion in Q2 2021.
  • A 5-year average of $5.6 billion and a median of $5.6 billion in 2023 define the central range for Shares Outstanding (Weighted Average).
  • Peak YoY movement for Shares Outstanding (Weighted Average): increased 0.94% in 2021, then fell 0.05% in 2022.
  • Pfizer's Shares Outstanding (Weighted Average) stood at $5.6 billion in 2021, then rose by 0.12% to $5.6 billion in 2022, then grew by 0.62% to $5.6 billion in 2023, then grew by 0.37% to $5.7 billion in 2024, then rose by 0.34% to $5.7 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Shares Outstanding (Weighted Average) are $5.7 billion (Q4 2025), $5.7 billion (Q3 2025), and $5.7 billion (Q2 2025).